Journal article
Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices
E Athan, VH Chu, P Tattevin, C Selton-Suty, P Jones, C Naber, JM Miró, S Ninot, N Fernández-Hidalgo, E Durante-Mangoni, D Spelman, B Hoen, T Lejko-Zupanc, E Cecchi, F Thuny, MM Hannan, P Pappas, M Henry, VG Fowler, AL Crowley Show all
JAMA | Published : 2012
Abstract
Context: Infection of implantable cardiac devices is an emerging disease with significant morbidity, mortality, and health care costs. Objectives: To describe the clinical characteristics and outcome of cardiac device infective endocarditis (CDIE) with attention to its health care association and to evaluate the association between device removal during index hospitalization and outcome. Design, Setting, and Patients: Prospective cohort study using data from the International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS), conducted June 2000 through August 2006 in 61 centers in 28 countries. Patients were hospitalized adults with definite endocarditis as defined by modifie..
View full abstractGrants
Awarded by Spanish Network for Research in Infectious Diseases
Awarded by Instituto de Salud Carlos III, Madrid, Spain
Funding Acknowledgements
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Chu reported receiving a career development award from the American Heart Association. Dr Tattevin reported receiving travel support to attend a meeting from Novartis. Dr Miro reported serving on the advisory boards of Cubist and Novartis; serving as a consultant for Abbott, Bristol-Myers Squibb, Cubist, Gilead Sciences, Merck, Novartis, Pfizer, and Theravance; receiving grants or grants pending from Cubist, Novartis, Fondo de Investigaciones Sanitarias (FIS, Spanish Ministry of Health), the National Institutes of Health, and RIS-III (Spanish Network for AIDS Research); and receiving payment for lectures from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Cubist, GlaxoSmithKline, Gilead Sciences, Janssen-Cilag, MSD, Novartis, Pfizer, Roche, Schering-Plough, Theravance, and ViiV. Dr Durante-Mangoni reported receiving payment for lectures from Novartis. Dr Hannan reported receiving an educational travel grant from Pfizer and receiving travel grants to attend international meetings from Pfizer and MSD. Dr Fowler reported serving as a consultant for Astellas, Cubist, Merck, Johnson & Johnson, Galderma, NovaDigm, The Medicines Company, Biosynexus, MedImmune, Novartis, and Pfizer; receiving grants or grants pending from the National Institutes of Health, Astellas, Cubist, Merck, Theravance, Cerexa, Pfizer, Novartis, Advanced Liquid Logic, and MedImmune; holding a patent (planned, pending, or issued) for a diagnostic approach; receiving royalties from UpToDate; and receiving honoraria for development of educational presentations from Arpida, Astellas, Cubist, Inhibitex, Merck, Pfizer, Targanta, Theravance, Wyeth, Ortho-McNeil, Novartis, Vertex Pharmaceuticals, and MedImmune. Dr Wang reported providing expert testimony for trial defense; receiving grants or grants pending from Gilead Sciences, Edwards Lifesciences, and Abbott Vascular; receiving payment for lectures from American Physician; receiving royalties for serving as an editor from Springer; and receiving payment for development of educational presentations from the American College of Cardiology Foundation. No other authors reported disclosures. None of the investigators received compensation for participation in ICE-PCS. This work was supported in part by grants from the Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Madrid, Spain, and the Spanish Network for Research in Infectious Diseases (REIPI RD06/0008). Dr Miro holds an INT10/219 Intensification Research Grant (I3SNS & PRICS programs) from the Instituto de Salud Carlos III, Madrid, Spain, and the Departament de Salut de la Generalitat de Catalunya, Barcelona, Spain.